Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × abexinostat × Clear all
NCT01543763 2025-03-21

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

University of California, San Francisco

Phase 1 Completed
90 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡